There are already scarce post-marketing experiences of cases of intestinal obstruction, and exacerbation of diverticulitis, several of which have required health-related intervention to eliminate the tablet. Patients with fundamental GI Ailments like esophageal cancer or colon cancer with a small gastrointestinal lumen are at higher threat of estab